GlassScriptPhysician profile
Kelli M Cocke
NPI 1922219674
$3,194.66
in general payments reported to CMS, 2019-2025
21 companies · $625 in 2025
The $625 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $246 · 2021: $269 · 2022: $578 · 2023: $411 · 2024: $826 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,861.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $874.75 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $690.35 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $379.32 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $243.61 | 2019-2024 | Dyanavel Xr, Onyda Xr |
| Adlon Therapeutics L.P. | $162.01 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.66 | 2020-2022 | |
| Aytu Biopharma, INC. | $104.91 | 2024-2025 | Karbinal |
| Collegium Pharmaceutical, INC. | $88.47 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $77.81 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $75.25 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $72.74 | 2019-2022 | |
| Pfizer INC. | $58.57 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $44.61 | 2025 | Zoryve |
| Neos Therapeutics, LP | $44.02 | 2019-2024 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Seqirus USA INC | $26.64 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhodes Pharmaceuticals L.P. | $23.33 | 2019 | |
| Vertical Pharmaceuticals, LLC | $21.84 | 2020 | |
| Verrica Pharmaceuticals INC. | $19.70 | 2025 | Ycanth |
| Sarepta Therapeutics, INC. | $18.68 | 2019 | |
| Sobi, INC | $15.84 | 2020 | |
| Shire North American Group INC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Cocke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.